PubMed Health⌕ Search
Home/Archive/PubMed

PubMed · 8761779

[Malignant keratoma].

I Sanou·L K Kam·A Traoré·A S Sawadogo·I D Zongo·B Zeba·B D Benon
View original source ↗Export metadata ↓

Abstract

INTRODUCTION: Birth of an Harlequin fetus in an African maternity ward is an exceptional event. There is no question as to the diagnosis, but no treatment is available. CASE REPORT: A female infant was delivered with typical lesions of malignant keratoma. Death occurred 20 hours after birth. DISCUSSION: In countries with adequate intensive care facilities (hydration, acitretine), such infants may occasionally survive with the risk of developing major lamellar ichthyosis which remains a handicap for the rest of life. In Burkina-Faso, such therapeutic facilities are lacking as are means of antenatal diagnosis. The ethical question as to whether or not to attempt survival measures is quite different under these conditions.

Explore related subjects

Burkina FasoFemaleFetal DiseasesHumansInfant, NewbornKeratosisPregnancyCase ReportsEnglish AbstractJournal Article

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

I Sanou, L K Kam, A Traoré, A S Sawadogo, I D Zongo, B Zeba, B D Benon. 1996. [Malignant keratoma].. https://pubmed.ncbi.nlm.nih.gov/8761779/

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

PubMed2006

Methylene blue for malaria in Africa: results from a dose-finding study in combination with chloroquine.

The development of safe, effective and affordable drug combinations against malaria in Africa is a public health priority. Methylene blue (MB) has a similar mode of action as chloroquine (CQ) and has moreover been shown to selectively inhibit the Plasmodium falciparum glutathione reductase. In 2004, an uncontrolled dose-finding study on the combination MB-CQ was performed in 435 young children with uncomplicated falciparum malaria in Burkina Faso (CQ monotherapy had a > 50% clinical failure rate in this area in 2003). Three serious adverse events (SAE) occurred of which one was probably attributable to the study medication. In the per protocol safety analysis, there were no dose specific effects. The overall clinical and parasitological failure rates by day 14 were 10% [95% CI (7.5%, 14.0%)] and 24% [95% CI (19.4%, 28.3%)], respectively. MB appears to have efficacy against malaria, but the combination of CQ-MB is clearly not effective in the treatment of malaria in Africa.

Burkina Faso↗